Last reviewed 2026-06-03 · How we verify

PCM/Oxy2

Maastricht University Medical Center · FDA-approved active Small molecule Under review

PCM/Oxy2 is a Opioid analgesic combination Small molecule drug developed by Maastricht University Medical Center. It is currently FDA-approved for Moderate-to-severe acute and chronic pain.

PCM/Oxy2 is a fixed-dose combination of paracetamol (acetaminophen) and oxycodone that provides analgesia through dual mechanisms: paracetamol's antipyretic and analgesic effects via COX inhibition, and oxycodone's opioid receptor agonism for moderate-to-severe pain relief.

PCM/Oxy2 is a small molecule intervention studied in a clinical trial for postoperative pain after ambulatory surgery. The exact mechanism of PCM/Oxy2 is not specified in the provided information, but it is classified as a small molecule.

At a glance

Generic name	PCM/Oxy2
Sponsor	Maastricht University Medical Center
Drug class	Opioid analgesic combination
Target	Mu opioid receptor (oxycodone); COX enzymes (paracetamol)
Modality	Small molecule
Therapeutic area	Pain Management
Phase	FDA-approved

Mechanism of action

Paracetamol reduces pain and fever through inhibition of cyclooxygenase enzymes in the central nervous system. Oxycodone is a semi-synthetic opioid agonist that binds to mu, delta, and kappa opioid receptors in the brain and spinal cord, enhancing pain modulation. The combination allows for synergistic analgesia at lower individual doses, potentially reducing opioid-related adverse effects while maintaining efficacy.

Approved indications

Moderate-to-severe acute and chronic pain

Common side effects

Nausea
Constipation
Dizziness
Drowsiness
Hepatotoxicity (paracetamol-related)

Key clinical trials

Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PCM/Oxy2 CI brief — competitive landscape report
PCM/Oxy2 updates RSS · CI watch RSS
Maastricht University Medical Center portfolio CI

Frequently asked questions about PCM/Oxy2

What is PCM/Oxy2?

PCM/Oxy2 is a Opioid analgesic combination drug developed by Maastricht University Medical Center, indicated for Moderate-to-severe acute and chronic pain.

How does PCM/Oxy2 work?

What is PCM/Oxy2 used for?

PCM/Oxy2 is indicated for Moderate-to-severe acute and chronic pain.

Who makes PCM/Oxy2?

PCM/Oxy2 is developed and marketed by Maastricht University Medical Center (see full Maastricht University Medical Center pipeline at /company/maastricht-university-medical-center).

What drug class is PCM/Oxy2 in?

PCM/Oxy2 belongs to the Opioid analgesic combination class. See all Opioid analgesic combination drugs at /class/opioid-analgesic-combination.

What development phase is PCM/Oxy2 in?

PCM/Oxy2 is FDA-approved (marketed).

What are the side effects of PCM/Oxy2?

Common side effects of PCM/Oxy2 include Nausea, Constipation, Dizziness, Drowsiness, Hepatotoxicity (paracetamol-related).

What does PCM/Oxy2 target?

PCM/Oxy2 targets Mu opioid receptor (oxycodone); COX enzymes (paracetamol) and is a Opioid analgesic combination.

Drug class: All Opioid analgesic combination drugs
Target: All drugs targeting Mu opioid receptor (oxycodone); COX enzymes (paracetamol)
Manufacturer: Maastricht University Medical Center — full pipeline
Therapeutic area: All drugs in Pain Management
Indication: Drugs for Moderate-to-severe acute and chronic pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing